These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11522012)

  • 21. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.
    Pimenta DC; Nantes IL; de Souza ES; Le Bonniec B; Ito AS; Tersariol IL; Oliveira V; Juliano MA; Juliano L
    Biochem J; 2002 Sep; 366(Pt 2):435-46. PubMed ID: 12000310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thrombosis and lung cancer].
    Bréchot JM
    Rev Mal Respir; 2005 Dec; 22(6 Pt 2):8S33-7. PubMed ID: 16340833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hospital-based costs associated with venous thromboembolism treatment regimens.
    Merli G; Ferrufino C; Lin J; Hussein M; Battleman D
    J Thromb Haemost; 2008 Jul; 6(7):1077-86. PubMed ID: 18445118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin in thrombosis and cancer.
    Mousa SA
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():25-30. PubMed ID: 15085463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma protein binding properties to immobilized heparin and heparin-albumin conjugate.
    Mirow N; Zimmermann B; Maleszka A; Knobl H; Tenderich G; Koerfer R; Herberg FW
    Artif Organs; 2007 Jun; 31(6):466-71. PubMed ID: 17537059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfractionated heparin and other antithrombin mediated anticoagulants.
    Adler BK
    Clin Lab Sci; 2004; 17(2):113-7. PubMed ID: 15168893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
    Noble SI; Hood K; Finlay IG
    Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venous thromboembolism in cancer patients undergoing major surgery.
    Osborne NH; Wakefield TW; Henke PK
    Ann Surg Oncol; 2008 Dec; 15(12):3567-78. PubMed ID: 18841419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic therapy and survival in cancer patients.
    Kakkar AK
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):147-51. PubMed ID: 19285281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparanase, heparin and the coagulation system in cancer progression.
    Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
    Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies.
    ten Cate-Hoek AJ; Prins MH
    Thromb Res; 2008; 122(5):584-98. PubMed ID: 17996281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
    Pruemer J
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns.
    Sissi C; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2003 Dec; 29(6):661-70. PubMed ID: 14719183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heparin and cancer].
    Lykke J
    Ugeskr Laeger; 2006 Dec; 168(50):4397-401. PubMed ID: 17217864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.